Revenue for oncology drugs, such as Merck's blockbuster drug Keytruda, rose significantly in 2020 compared to the year prior, according to data from S&P Global.
Keytruda, used to treat a number of cancers, including breast cancer and skin cancer, generated more revenue than any other oncology drug last year — $14.38 billion — a 29.7 percent increase over 2019.
The next best-selling oncology drug in 2020 was Bristol Myers Squibb's Revlimid, at $12.11 billion. Bristol Myers Squibb's Opdivo was one of the few oncology drugs that saw revenue fall last year, down 2.9 percent to $6.99 billion, according to S&P Global.
Find the full report here.
More articles on pharmacy:
240 million Americans could get fully vaccinated against COVID-19 in 3 months
Rising costs force 39% of Americans to skip, ration meds, survey says
Millions of J&J vaccines going unused